Literature DB >> 29020318

Reply to Rossi et al.

Michelle S Hsiang1,2,3, Nikhil Ranadive4,5, Stanley Chitundu6, Nyasatu Ntshalintshali7, Bryan Greenhouse8.   

Abstract

Entities:  

Mesh:

Year:  2017        PMID: 29020318      PMCID: PMC5850315          DOI: 10.1093/cid/cix627

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


× No keyword cloud information.
To the Editor—We thank Rossi and colleagues for sharing their findings from Cambodia [1], which complement our recent article reporting limitations of rapid diagnostic testing in patients with suspected malaria from Swaziland, a low-endemic country in southern Africa aiming to eliminate malaria [2]. Using polymerase chain reaction (PCR) as gold standard, they performed a diagnostic accuracy evaluation of rapid diagnostic testing (RDT) to diagnose Plasmodium falciparum in subjects with suspected malaria. Sensitivity was low at 72% (compared to 52% in our study). Low-density infection, defined as <100 parasites/μL, explained 75% of false-negative results (compared to 76% in our study). With the large sample size of 4382 patients, sampling of all RDT negatives (vs selective sampling employed in our study), and use of quantitative PCR, the study is a useful addition to the few published studies on performance of RDT to assess symptomatic malaria in low-transmission settings [1, 3, 4]. As malaria transmission declines, the proportion of low-density infection among symptomatic as well as asymptomatic individuals increases [5-7]. It is generally assumed that symptomatic individuals will present with high-density infection; however, low-density infections accounted for 24% of all PCR-positive cases, compared to 22% in our study (taking into accounting the sampling of RDT negatives). Given the low prevalence of infection in these settings [8, 9], the unexpectedly high proportion of low-density infection cannot solely be explained by background parasitemia. Rather, patients in low-endemic settings may have a lower pyrogenic threshold for malaria due to decreased immunity, other host factors, or virulence of the parasite [10]. Interestingly, Plasmodium falciparum strains from Cambodia have been associated with a lower pyrogenic threshold than some African and American strains [10]. Early access to care, before the parasite has undergone multiple cycles of replication, would be facilitated by village malaria workers in the Rossi et al study and may also explain the low parasite densities observed. Missed low-density infections represent missed opportunities to prevent further transmission. They also represent missed opportunities for transmission reduction activities in the community, as passively identified cases may trigger targeted interventions such as active case detection and vector control. On the flip side, overdiagnosis is also a problem. We would like to note that the false-positivity rates, or the percentage of healthy individuals who incorrectly receive a positive test result, were incorrectly reported in both studies. The correct false-positive rates were low at 5.9% in Swaziland and 0.3% in Cambodia (not 32% and 11%, respectively). However, due to the low prevalence of malaria, positive predictive values (PPVs) were compromised. Rossi et al report a higher PPV than our study (89%, compared to 67% in Swaziland), but a PPV of 89% still equates to overtreatment in roughly one-tenth of patients, and potential “overintervention” in the communities where activities were triggered by passively detected cases. A new RDT with reported sensitivity 10 times higher than current RDTs has recently been launched. While its use has potential to reduce transmission [11], there may be compromises in specificity due to the fact that the target antigen can persist in the bloodstream for several weeks, despite clearance of infection. Confirmatory testing with a highly specific test, as is done with human immunodeficiency virus testing, may be one solution. Certainly, as alternative diagnostic approaches are being considered for malaria, the balance of predictive values, sensitivity, specificity, as well as impact at individual and community levels, will need to be thoughfully considered.
  11 in total

1.  Evaluation of the pyrogenic threshold for Plasmodium falciparum malaria in naive individuals.

Authors:  Michelle L Gatton; Qin Cheng
Journal:  Am J Trop Med Hyg       Date:  2002-05       Impact factor: 2.345

Review 2.  Malaria rapid diagnostic tests in elimination settings--can they find the last parasite?

Authors:  M L McMorrow; M Aidoo; S P Kachur
Journal:  Clin Microbiol Infect       Date:  2011-09-13       Impact factor: 8.067

3.  Performance of Rapid Diagnostic Testing in Patients with Suspected Malaria in Cambodia, a Low-Endemicity Country Aiming for Malaria Elimination.

Authors:  Gabriele Rossi; Martin De Smet; Nimol Khim; Jean-Marie Kindermans; Didier Menard
Journal:  Clin Infect Dis       Date:  2017-10-30       Impact factor: 9.079

Review 4.  Rapid diagnostic tests for diagnosing uncomplicated P. falciparum malaria in endemic countries.

Authors:  Katharine Abba; Jonathan J Deeks; Piero Olliaro; Cho-Min Naing; Sally M Jackson; Yemisi Takwoingi; Sarah Donegan; Paul Garner
Journal:  Cochrane Database Syst Rev       Date:  2011-07-06

5.  Changing malaria epidemiology and diagnostic criteria for Plasmodium falciparum clinical malaria.

Authors:  Clémentine Roucher; Christophe Rogier; Fambaye Dieye-Ba; Cheikh Sokhna; Adama Tall; Jean-François Trape
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

6.  Surveillance for malaria elimination in Swaziland: a national cross-sectional study using pooled PCR and serology.

Authors:  Michelle S Hsiang; Jimee Hwang; Simon Kunene; Chris Drakeley; Deepika Kandula; Joseph Novotny; Justin Parizo; Trevor Jensen; Marcus Tong; Jordan Kemere; Sabelo Dlamini; Bruno Moonen; Evelina Angov; Sheetij Dutta; Christian Ockenhouse; Grant Dorsey; Bryan Greenhouse
Journal:  PLoS One       Date:  2012-01-06       Impact factor: 3.240

7.  The usefulness of rapid diagnostic tests in the new context of low malaria transmission in Zanzibar.

Authors:  Delér Shakely; Kristina Elfving; Berit Aydin-Schmidt; Mwinyi I Msellem; Ulrika Morris; Rahila Omar; Xu Weiping; Max Petzold; Bryan Greenhouse; Kimberly A Baltzell; Abdullah S Ali; Anders Björkman; Andreas Mårtensson
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

Review 8.  Mathematical Modelling to Guide Drug Development for Malaria Elimination.

Authors:  Hannah C Slater; Lucy C Okell; Azra C Ghani
Journal:  Trends Parasitol       Date:  2016-10-07

9.  Limitations of Rapid Diagnostic Testing in Patients with Suspected Malaria: A Diagnostic Accuracy Evaluation from Swaziland, a Low-Endemicity Country Aiming for Malaria Elimination.

Authors:  Nikhil Ranadive; Simon Kunene; Sarah Darteh; Nyasatu Ntshalintshali; Nomcebo Nhlabathi; Nomcebo Dlamini; Stanley Chitundu; Manik Saini; Maxwell Murphy; Adam Soble; Alanna Schwartz; Bryan Greenhouse; Michelle S Hsiang
Journal:  Clin Infect Dis       Date:  2017-05-01       Impact factor: 9.079

10.  Plasmodium prevalence and artemisinin-resistant falciparum malaria in Preah Vihear Province, Cambodia: a cross-sectional population-based study.

Authors:  Philippe Bosman; Jorgen Stassijns; Fabienne Nackers; Lydie Canier; Nimol Kim; Saorin Khim; Sweet C Alipon; Meng Chuor Char; Nguon Chea; Lek Dysoley; Rafael Van den Bergh; William Etienne; Martin De Smet; Didier Ménard; Jean-Marie Kindermans
Journal:  Malar J       Date:  2014-10-06       Impact factor: 2.979

View more
  1 in total

1.  Active Case Finding for Malaria: A 3-Year National Evaluation of Optimal Approaches to Detect Infections and Hotspots Through Reactive Case Detection in the Low-transmission Setting of Eswatini.

Authors:  Michelle S Hsiang; Nyasatu Ntshalintshali; Mi-Suk Kang Dufour; Nomcebo Dlamini; Nomcebo Nhlabathi; Sibonakaliso Vilakati; Calsile Malambe; Zulisile Zulu; Gugu Maphalala; Joseph Novotny; Maxwell Murphy; Alanna Schwartz; Hugh Sturrock; Roly Gosling; Grant Dorsey; Simon Kunene; Bryan Greenhouse
Journal:  Clin Infect Dis       Date:  2020-03-17       Impact factor: 9.079

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.